-transparent.png){kind=logo}
In patients after mechanical heart valve replacement anticoagulation is required for the prevention of thrombotic and thromboembolic events. In this setting oral anticoagulation can only be performed with vitamin K antagonists (VKA), while currently all available non-vitamin K dependent oral anticoagulants (NOAC) are contraindicated in patients with mechanical heart valve replacement. This review deals with anticoagulation in patients with mechanical heart valve replacement as well as coagulation inhibition after bioprosthetic or percutaneous valve replacement. In addition, recommendations are given for antithrombotic medication in patients with mechanical heart valve replacement in various clinical scenarios.
Frederik Voss, and
Christoph Sucker, and
Jens Litmathe
January 2002,
The Journal of heart valve disease,
Frederik Voss, and
Christoph Sucker, and
Jens Litmathe
January 2015,
Cardiovascular & hematological disorders drug targets,
Frederik Voss, and
Christoph Sucker, and
Jens Litmathe
November 2016,
The American journal of cardiology,
Frederik Voss, and
Christoph Sucker, and
Jens Litmathe
April 2003,
Zhonghua wai ke za zhi [Chinese journal of surgery],
Frederik Voss, and
Christoph Sucker, and
Jens Litmathe
January 2002,
West African journal of medicine,
Frederik Voss, and
Christoph Sucker, and
Jens Litmathe
June 2006,
The Journal of thoracic and cardiovascular surgery,
Frederik Voss, and
Christoph Sucker, and
Jens Litmathe
November 2010,
The Journal of thoracic and cardiovascular surgery,
Frederik Voss, and
Christoph Sucker, and
Jens Litmathe
July 2016,
The Annals of thoracic surgery,
Frederik Voss, and
Christoph Sucker, and
Jens Litmathe
May 2008,
The Journal of heart valve disease,
Frederik Voss, and
Christoph Sucker, and
Jens Litmathe
March 1991,
Deutsche medizinische Wochenschrift (1946),
